| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ZAQ; PKR1; GPR73; PK-R1; GPR73a |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human PROKR1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PROKR1抗体的参考文献示例(注：以下内容为模拟示例，实际文献需通过学术数据库核实)：
1. **文献名称**: "PROKR1 Expression in Endometriosis: A Novel Biomarker for Disease Severity"
**作者**: Smith A, et al.
**摘要**: 该研究通过免疫组化技术使用PROKR1抗体，发现子宫内膜异位症患者的病变组织中PROKR1表达显著上调，且与疼痛症状和疾病分期呈正相关，提示其作为潜在治疗靶点的可能性。
2. **文献名称**: "Development of a Monoclonal Antibody Targeting PROKR1 for Anti-Angiogenic Therapy"
**作者**: Johnson B, et al.
**摘要**: 研究团队开发了一种高特异性PROKR1单克隆抗体，体外实验显示其能有效抑制血管内皮细胞迁移和管腔形成，动物模型中显著减少肿瘤血管生成，为抗癌治疗提供新策略。
3. **文献名称**: "PROKR1 Signaling in Neuropathic Pain: Insights from Antibody-Mediated Receptor Blockade"
**作者**: Lee C, et al.
**摘要**: 通过使用PROKR1中和抗体阻断受体活性，研究发现PROKR1在神经损伤模型中介导疼痛信号传递，抗体干预可减轻小鼠机械性痛觉超敏，为镇痛药物开发提供依据。
4. **文献名称**: "PROKR1 Overexpression in Colorectal Cancer Metastasis Detected by Immunohistochemical Staining"
**作者**: Zhang Y, et al.
**摘要**: 利用PROKR1抗体进行组织染色，发现结肠癌转移灶中PROKR1蛋白表达水平显著高于原发肿瘤，提示其可能作为预测转移风险的生物标志物。
建议通过PubMed、Web of Science等平台以“PROKR1 antibody”、“PROKR1 receptor”等关键词检索最新文献以获取真实数据。
PROKR1 (Prokineticin Receptor 1) is a G protein-coupled receptor that binds prokineticins, small secreted proteins involved in diverse physiological processes, including angiogenesis, pain perception, neurogenesis, and inflammatory responses. The receptor is encoded by the PROKR1 gene and is expressed in various tissues, such as the brain, endocrine glands, gastrointestinal tract, and immune cells. Dysregulation of PROKR1 signaling has been implicated in pathological conditions, including cancer progression, chronic pain syndromes, and reproductive disorders.
Antibodies targeting PROKR1 are essential tools for studying its expression, localization, and functional roles. These antibodies are typically developed using immunogens derived from specific regions of the receptor, such as extracellular or intracellular domains, to ensure specificity. Validated applications include Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Researchers rely on PROKR1 antibodies to investigate receptor-protein interactions, signaling pathways (e.g., MAPK/ERK or calcium mobilization), and therapeutic targeting in disease models.
Commercial PROKR1 antibodies are often characterized for species reactivity (e.g., human, mouse, rat) and tested for cross-reactivity with PROKR2. a closely related receptor. Proper validation using knockout controls or siRNA knockdown is critical to confirm specificity. Recent studies highlight PROKR1's potential as a biomarker or drug target, particularly in cancers like glioblastoma and colorectal adenocarcinoma, where its overexpression correlates with aggressive phenotypes.
×
